Heart failure & cardiomyopathies
Randomized Investigation of Heart Failure Therapy in Patients with Advanced Cancer at Risk of Cardiac Wasting: Rationale and Design of the EMPATICC Trial
Study context
- Population
- Stage IV solid tumours, palliative care, 1–6 month life expectancy, with CV risk and functional limitationcompleted randomization
- Participants
- 93 participants
- Planned comparison
- Optimized heart failure (HF) therapy plus usual care vs usual care alone
- Primary endpoint
- Hierarchical composite (win ratio): days alive and able to wash, 4 m walking ability, patient global assessment of well-being
Methodological detailsrationale and design, multicentre, investigator-initiated, double-blind, proof-of-concept, 30-day open-label extension, Enrolment ended 30 January 2025
- Rationale and design
- Multicentre
- Investigator-initiated
- Double-blind
- Proof-of-concept
- 30-day open-label extension
- Enrolment ended 30 January 2025
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Randomized Investigation of Heart Failure Therapy in Patients with Advanced Cancer at Risk of Cardiac Wasting: Rationale and Design of the EMPATICC Trial. Eur J Heart Fail. Published 26 August 2025. doi:10.
Summarised from the published abstract; every number is checked against it